Ruxolitinib View Full Text


Ontology type: schema:Chapter     


Chapter Info

DATE

2014-04-23

AUTHORS

Heiko Becker , Monika Engelhardt , Nikolas von Bubnoff , Ralph Wäsch

ABSTRACT

Ruxolitinib, formerly known as INCB018424 or INC424, is a potent and selective oral inhibitor of JAK1 and JAK2. Ruxolitinib has been approved for the treatment of myelofibrosis, which is characterized, biologically, by the activation of the JAK-STAT pathway and, clinically, by bone marrow fibrosis, splenomegaly, abnormal blood counts, and poor quality-of-life through associated symptoms. Ruxolitinib treatment results in a meaningful reduction in spleen size and symptom burden in the majority of myelofibrosis patients, and it may also have a favorable effect on survival. Treatment response apparently does not depend on the presence of a JAK2 V617F mutation. The predominant toxicities are thrombocytopenia and anemia. The metabolization of ruxolitinib through CYP3A4 needs to be considered particularly if co-administered with potent CYP3A4 inhibitors. Several further JAK inhibitors are currently studied in myelofibrosis or other immuno-inflammatory diseases. More... »

PAGES

249-257

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/978-3-642-54490-3_16

DOI

http://dx.doi.org/10.1007/978-3-642-54490-3_16

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1027114852

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/24756798


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Animals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Janus Kinase 1", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Janus Kinase 2", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Nitriles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Primary Myelofibrosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Protein Kinase Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyrazoles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyrimidines", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University Freiburg\u2014Medical Center, Hugstetterstrasse 55, 79106, Freiburg, Germany", 
          "id": "http://www.grid.ac/institutes/grid.5963.9", 
          "name": [
            "University Freiburg\u2014Medical Center, Hugstetterstrasse 55, 79106, Freiburg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Becker", 
        "givenName": "Heiko", 
        "id": "sg:person.0631556757.06", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0631556757.06"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University Freiburg\u2014Medical Center, Hugstetterstrasse 55, 79106, Freiburg, Germany", 
          "id": "http://www.grid.ac/institutes/grid.5963.9", 
          "name": [
            "University Freiburg\u2014Medical Center, Hugstetterstrasse 55, 79106, Freiburg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Engelhardt", 
        "givenName": "Monika", 
        "id": "sg:person.01216502565.63", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01216502565.63"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University Freiburg\u2014Medical Center, Hugstetterstrasse 55, 79106, Freiburg, Germany", 
          "id": "http://www.grid.ac/institutes/grid.5963.9", 
          "name": [
            "University Freiburg\u2014Medical Center, Hugstetterstrasse 55, 79106, Freiburg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "von Bubnoff", 
        "givenName": "Nikolas", 
        "id": "sg:person.0662205755.90", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0662205755.90"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University Freiburg\u2014Medical Center, Hugstetterstrasse 55, 79106, Freiburg, Germany", 
          "id": "http://www.grid.ac/institutes/grid.5963.9", 
          "name": [
            "University Freiburg\u2014Medical Center, Hugstetterstrasse 55, 79106, Freiburg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "W\u00e4sch", 
        "givenName": "Ralph", 
        "id": "sg:person.01151333006.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01151333006.25"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2014-04-23", 
    "datePublishedReg": "2014-04-23", 
    "description": "Ruxolitinib, formerly known as INCB018424 or INC424, is a potent and selective oral inhibitor of JAK1 and JAK2. Ruxolitinib has been approved for the treatment of myelofibrosis, which is characterized, biologically, by the activation of the JAK-STAT pathway and, clinically, by bone marrow fibrosis, splenomegaly, abnormal blood counts, and poor quality-of-life through associated symptoms. Ruxolitinib treatment results in a meaningful reduction in spleen size and symptom burden in the majority of myelofibrosis patients, and it may also have a favorable effect on survival. Treatment response apparently does not depend on the presence of a JAK2 V617F mutation. The predominant toxicities are thrombocytopenia and anemia. The metabolization of ruxolitinib through CYP3A4 needs to be considered particularly if co-administered with potent CYP3A4 inhibitors. Several further JAK inhibitors are currently studied in myelofibrosis or other immuno-inflammatory diseases.", 
    "editor": [
      {
        "familyName": "Martens", 
        "givenName": "Uwe M.", 
        "type": "Person"
      }
    ], 
    "genre": "chapter", 
    "id": "sg:pub.10.1007/978-3-642-54490-3_16", 
    "isAccessibleForFree": false, 
    "isPartOf": {
      "isbn": [
        "978-3-642-54489-7", 
        "978-3-642-54490-3"
      ], 
      "name": "Small Molecules in Oncology", 
      "type": "Book"
    }, 
    "keywords": [
      "immuno-inflammatory diseases", 
      "selective oral inhibitor", 
      "treatment of myelofibrosis", 
      "bone marrow fibrosis", 
      "potent CYP3A4 inhibitor", 
      "abnormal blood counts", 
      "JAK2 V617F mutation", 
      "predominant toxicity", 
      "symptom burden", 
      "oral inhibitor", 
      "marrow fibrosis", 
      "blood count", 
      "CYP3A4 inhibitors", 
      "spleen size", 
      "treatment response", 
      "myelofibrosis patients", 
      "JAK inhibitors", 
      "treatment results", 
      "ruxolitinib", 
      "V617F mutation", 
      "meaningful reduction", 
      "favorable effect", 
      "myelofibrosis", 
      "inhibitors", 
      "poor quality", 
      "splenomegaly", 
      "thrombocytopenia", 
      "patients", 
      "INCB018424", 
      "fibrosis", 
      "anemia", 
      "symptoms", 
      "CYP3A4", 
      "disease", 
      "survival", 
      "treatment", 
      "burden", 
      "JAK2", 
      "toxicity", 
      "activation", 
      "count", 
      "JAK1", 
      "JAK", 
      "majority", 
      "pathway", 
      "mutations", 
      "metabolization", 
      "response", 
      "life", 
      "reduction", 
      "effect", 
      "presence", 
      "quality", 
      "results", 
      "size"
    ], 
    "name": "Ruxolitinib", 
    "pagination": "249-257", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1027114852"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/978-3-642-54490-3_16"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "24756798"
        ]
      }
    ], 
    "publisher": {
      "name": "Springer Nature", 
      "type": "Organisation"
    }, 
    "sameAs": [
      "https://doi.org/10.1007/978-3-642-54490-3_16", 
      "https://app.dimensions.ai/details/publication/pub.1027114852"
    ], 
    "sdDataset": "chapters", 
    "sdDatePublished": "2022-11-24T21:17", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221124/entities/gbq_results/chapter/chapter_389.jsonl", 
    "type": "Chapter", 
    "url": "https://doi.org/10.1007/978-3-642-54490-3_16"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/978-3-642-54490-3_16'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/978-3-642-54490-3_16'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/978-3-642-54490-3_16'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/978-3-642-54490-3_16'


 

This table displays all metadata directly associated to this object as RDF triples.

175 TRIPLES      22 PREDICATES      89 URIs      82 LITERALS      17 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/978-3-642-54490-3_16 schema:about N0886b9b0f57048d6a266760231beef0e
2 N09786d5d6a944f9f89a51ffa8d0481da
3 N2d442fc16e6244c0ad61aef57fe54ced
4 N481fdf0222c44597ae4c8d605b8b9b83
5 N605de21a37a54e28a0d1278306ded036
6 N6ea2475c060046ab97989212110d4ff8
7 N91a244d1504941828333186e95200a6d
8 Nd31e01376ede41369bd20ef0b67d5c2a
9 Ne643d254f49540e089322910f65342d2
10 anzsrc-for:11
11 anzsrc-for:1102
12 schema:author Na2e41a46d8ee4ff4ad1b0f680e52a1e3
13 schema:datePublished 2014-04-23
14 schema:datePublishedReg 2014-04-23
15 schema:description Ruxolitinib, formerly known as INCB018424 or INC424, is a potent and selective oral inhibitor of JAK1 and JAK2. Ruxolitinib has been approved for the treatment of myelofibrosis, which is characterized, biologically, by the activation of the JAK-STAT pathway and, clinically, by bone marrow fibrosis, splenomegaly, abnormal blood counts, and poor quality-of-life through associated symptoms. Ruxolitinib treatment results in a meaningful reduction in spleen size and symptom burden in the majority of myelofibrosis patients, and it may also have a favorable effect on survival. Treatment response apparently does not depend on the presence of a JAK2 V617F mutation. The predominant toxicities are thrombocytopenia and anemia. The metabolization of ruxolitinib through CYP3A4 needs to be considered particularly if co-administered with potent CYP3A4 inhibitors. Several further JAK inhibitors are currently studied in myelofibrosis or other immuno-inflammatory diseases.
16 schema:editor N24dcfc0f08374e3193ca8371c55e50bd
17 schema:genre chapter
18 schema:isAccessibleForFree false
19 schema:isPartOf N49880d2a736b4906896aab6ab1a97d9b
20 schema:keywords CYP3A4
21 CYP3A4 inhibitors
22 INCB018424
23 JAK
24 JAK inhibitors
25 JAK1
26 JAK2
27 JAK2 V617F mutation
28 V617F mutation
29 abnormal blood counts
30 activation
31 anemia
32 blood count
33 bone marrow fibrosis
34 burden
35 count
36 disease
37 effect
38 favorable effect
39 fibrosis
40 immuno-inflammatory diseases
41 inhibitors
42 life
43 majority
44 marrow fibrosis
45 meaningful reduction
46 metabolization
47 mutations
48 myelofibrosis
49 myelofibrosis patients
50 oral inhibitor
51 pathway
52 patients
53 poor quality
54 potent CYP3A4 inhibitor
55 predominant toxicity
56 presence
57 quality
58 reduction
59 response
60 results
61 ruxolitinib
62 selective oral inhibitor
63 size
64 spleen size
65 splenomegaly
66 survival
67 symptom burden
68 symptoms
69 thrombocytopenia
70 toxicity
71 treatment
72 treatment of myelofibrosis
73 treatment response
74 treatment results
75 schema:name Ruxolitinib
76 schema:pagination 249-257
77 schema:productId N50f7cf952cff440baea855869e28a2e9
78 N7094d205e36548fea039c1aff820ee6d
79 Ncefc10d8ef9b46fcbda11f4253210076
80 schema:publisher N11df2fc4afc846f6a059525d0dcce654
81 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027114852
82 https://doi.org/10.1007/978-3-642-54490-3_16
83 schema:sdDatePublished 2022-11-24T21:17
84 schema:sdLicense https://scigraph.springernature.com/explorer/license/
85 schema:sdPublisher N0a2359db805c4a26ac965f9608d2bcc8
86 schema:url https://doi.org/10.1007/978-3-642-54490-3_16
87 sgo:license sg:explorer/license/
88 sgo:sdDataset chapters
89 rdf:type schema:Chapter
90 N078d983032174d2ea8b561728b4d3d06 rdf:first sg:person.0662205755.90
91 rdf:rest Na4cefb4e302b4b1fba2a3cf4d74208d6
92 N0886b9b0f57048d6a266760231beef0e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
93 schema:name Nitriles
94 rdf:type schema:DefinedTerm
95 N09786d5d6a944f9f89a51ffa8d0481da schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
96 schema:name Animals
97 rdf:type schema:DefinedTerm
98 N0a2359db805c4a26ac965f9608d2bcc8 schema:name Springer Nature - SN SciGraph project
99 rdf:type schema:Organization
100 N11df2fc4afc846f6a059525d0dcce654 schema:name Springer Nature
101 rdf:type schema:Organisation
102 N24dcfc0f08374e3193ca8371c55e50bd rdf:first N88265166b90544229b6533af6d15eb2c
103 rdf:rest rdf:nil
104 N2d442fc16e6244c0ad61aef57fe54ced schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
105 schema:name Humans
106 rdf:type schema:DefinedTerm
107 N481fdf0222c44597ae4c8d605b8b9b83 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Pyrazoles
109 rdf:type schema:DefinedTerm
110 N49880d2a736b4906896aab6ab1a97d9b schema:isbn 978-3-642-54489-7
111 978-3-642-54490-3
112 schema:name Small Molecules in Oncology
113 rdf:type schema:Book
114 N50f7cf952cff440baea855869e28a2e9 schema:name doi
115 schema:value 10.1007/978-3-642-54490-3_16
116 rdf:type schema:PropertyValue
117 N605de21a37a54e28a0d1278306ded036 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Protein Kinase Inhibitors
119 rdf:type schema:DefinedTerm
120 N6ea2475c060046ab97989212110d4ff8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Pyrimidines
122 rdf:type schema:DefinedTerm
123 N7094d205e36548fea039c1aff820ee6d schema:name pubmed_id
124 schema:value 24756798
125 rdf:type schema:PropertyValue
126 N88265166b90544229b6533af6d15eb2c schema:familyName Martens
127 schema:givenName Uwe M.
128 rdf:type schema:Person
129 N91a244d1504941828333186e95200a6d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Janus Kinase 2
131 rdf:type schema:DefinedTerm
132 Na2e41a46d8ee4ff4ad1b0f680e52a1e3 rdf:first sg:person.0631556757.06
133 rdf:rest Na91ccf5f381442899c7d8408649222b2
134 Na4cefb4e302b4b1fba2a3cf4d74208d6 rdf:first sg:person.01151333006.25
135 rdf:rest rdf:nil
136 Na91ccf5f381442899c7d8408649222b2 rdf:first sg:person.01216502565.63
137 rdf:rest N078d983032174d2ea8b561728b4d3d06
138 Ncefc10d8ef9b46fcbda11f4253210076 schema:name dimensions_id
139 schema:value pub.1027114852
140 rdf:type schema:PropertyValue
141 Nd31e01376ede41369bd20ef0b67d5c2a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Primary Myelofibrosis
143 rdf:type schema:DefinedTerm
144 Ne643d254f49540e089322910f65342d2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Janus Kinase 1
146 rdf:type schema:DefinedTerm
147 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
148 schema:name Medical and Health Sciences
149 rdf:type schema:DefinedTerm
150 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
151 schema:name Cardiorespiratory Medicine and Haematology
152 rdf:type schema:DefinedTerm
153 sg:person.01151333006.25 schema:affiliation grid-institutes:grid.5963.9
154 schema:familyName Wäsch
155 schema:givenName Ralph
156 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01151333006.25
157 rdf:type schema:Person
158 sg:person.01216502565.63 schema:affiliation grid-institutes:grid.5963.9
159 schema:familyName Engelhardt
160 schema:givenName Monika
161 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01216502565.63
162 rdf:type schema:Person
163 sg:person.0631556757.06 schema:affiliation grid-institutes:grid.5963.9
164 schema:familyName Becker
165 schema:givenName Heiko
166 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0631556757.06
167 rdf:type schema:Person
168 sg:person.0662205755.90 schema:affiliation grid-institutes:grid.5963.9
169 schema:familyName von Bubnoff
170 schema:givenName Nikolas
171 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0662205755.90
172 rdf:type schema:Person
173 grid-institutes:grid.5963.9 schema:alternateName University Freiburg—Medical Center, Hugstetterstrasse 55, 79106, Freiburg, Germany
174 schema:name University Freiburg—Medical Center, Hugstetterstrasse 55, 79106, Freiburg, Germany
175 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...